# A Trial of Episil® Oral Liquid in Cancer Patients Suffering From Chemotherapy- and/or Radiation-induced Oral Mucositis

> **NCT03546985** · NA · COMPLETED · sponsor: **Solasia Pharma K.K.** · enrollment: 60 (actual)

## Conditions studied

- Chemotherapy- and/or Radiation-induced Oral Mucositis

## Interventions

- **DEVICE:** episil®
- **DEVICE:** Kang Su

## Key facts

- **NCT ID:** NCT03546985
- **Lead sponsor:** Solasia Pharma K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-26
- **Primary completion:** 2018-05-08
- **Final completion:** 2018-05-25
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03546985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03546985, "A Trial of Episil® Oral Liquid in Cancer Patients Suffering From Chemotherapy- and/or Radiation-induced Oral Mucositis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03546985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*